Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) have been given a consensus recommendation of “Hold” by the nineteen research firms that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $48.17.
A number of research firms have commented on JUNO. Wedbush upgraded shares of Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 price objective on the stock in a research note on Tuesday, August 29th. Wells Fargo & Company restated an “outperform” rating and issued a $54.00 price objective (up from $35.00) on shares of Juno Therapeutics in a research note on Tuesday, September 5th. Raymond James Financial lifted their price objective on shares of Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Goldman Sachs Group restated a “neutral” rating and issued a $44.00 price objective on shares of Juno Therapeutics in a research note on Friday, October 6th. Finally, Standpoint Research restated a “reduce” rating on shares of Juno Therapeutics in a research note on Thursday, August 31st.
In other news, EVP Robert Azelby sold 6,666 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total transaction of $366,296.70. Following the transaction, the executive vice president now directly owns 79,998 shares in the company, valued at $4,395,890.10. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Sunil Agarwal sold 7,285 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Insiders own 15.08% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Capital International Investors acquired a new position in Juno Therapeutics during the third quarter worth about $256,339,000. Redmile Group LLC acquired a new position in Juno Therapeutics during the second quarter worth about $66,344,000. Jennison Associates LLC grew its position in Juno Therapeutics by 162.0% during the third quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock worth $89,213,000 after buying an additional 1,229,622 shares during the period. Orbimed Advisors LLC grew its position in Juno Therapeutics by 123.1% during the third quarter. Orbimed Advisors LLC now owns 2,041,608 shares of the biopharmaceutical company’s stock worth $91,587,000 after buying an additional 1,126,400 shares during the period. Finally, Capital Guardian Trust Co. acquired a new position in Juno Therapeutics during the third quarter worth about $37,400,000. Institutional investors and hedge funds own 70.37% of the company’s stock.
Shares of Juno Therapeutics (JUNO) opened at $47.41 on Thursday. Juno Therapeutics has a 1 year low of $17.52 and a 1 year high of $63.45. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The firm had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same period in the previous year, the company earned ($0.57) earnings per share. Juno Therapeutics’s quarterly revenue was up 115.4% compared to the same quarter last year. sell-side analysts forecast that Juno Therapeutics will post -4.02 EPS for the current fiscal year.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.